← Browse by Condition
Medical Condition

metastatic hepatocellular carcinoma

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1

ClinicalMetric tracks all active clinical trials for metastatic hepatocellular carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — metastatic hepatocellular carcinoma Clinical Trials

How many clinical trials are currently recruiting for metastatic hepatocellular carcinoma?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for metastatic hepatocellular carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for metastatic hepatocellular carcinoma?
metastatic hepatocellular carcinoma research spans Phase 1 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a metastatic hepatocellular carcinoma clinical trial?
Eligibility criteria for metastatic hepatocellular carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Top Sponsors
National Cancer Institute (NCI) 2 trials
M.D. Anderson Cancer Center 1 trial

Recruiting Clinical Trials

NCT06066138 Phase 1
Recruiting
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Enrollment
30 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT05092373 Phase 1
Recruiting
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Enrollment
43 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT05003895 Phase 1
Recruiting
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
Enrollment
38 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →

Related Conditions

locally advanced alveolar soft part sarcoma (1) metastatic alveolar soft part sarcoma (1) locally advanced non small cell lung cancer (1) metastatic non small cell lung cancer (1) locally advanced small cell lung cancer (1) metastatic small cell lung cancer (1) locally advanced hepatocellular carcinoma (1) locally advanced melanoma (1) metastatic melanoma (1) advanced breast carcinoma (1) advanced endometrial carcinoma (1) advanced fallopian tube carcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology